Post by Nucleate UK

From Scientific Discovery to a Biotech Company on the Rise 🚀 Giuseppe Mazza's PhD finding would have led to most people publishing a paper and moving on. Instead, he built Engitix Therapeutics. Mazza discovered that after stripping cells from a cirrhotic liver, the remaining extracellular matrix isn't just structurally different from healthy tissue, but is molecularly distinct, and actively primes new cells to become diseased. This insight sat untouched in drug development for years. Engitix made it into a platform. Our newest piece covers a decade-long journey: from a PhD at UCL, to $85M raised, partnerships with Takeda, Morphic, and GSK, and a first clinical entry targeted for 2027. The piece is now published on our Substack: link in the comments 👇 This piece is the second interview of our Biotech Founder's Playbook series, a Nucleate UK x Advanced Research + Invention Agency (ARIA) initiative documenting the early-stage spinout journeys that rarely get written down. Thank you to Giuseppe for being so candid, and to Gauhar Sagindykova and rest of the Spinout Fellowship team for conducting and writing the article. Andrea Brundin Anna Seggewisse Emma Watts Federico Caso Murray Cox Victor Kleshnev